Human rhinovirus 3C protease as a potential target for the development of antiviral agents
- PMID: 17305557
- DOI: 10.2174/138920307779941523
Human rhinovirus 3C protease as a potential target for the development of antiviral agents
Abstract
As the major cause of the common cold in children and adults, human rhinoviruses (HRVs) are a group of small single-stranded positive-sense RNA viruses. HRVs translate their genetic information into a polyprotein precursor that is mainly processed by a virally encoded 3C protease (3Cpro) to generate functional viral proteins and enzymes. It has been shown that the enzymatic activity of HRV 3Cpro is essential to viral replication. The 3Cpro is distinguished from most other proteases by the fact that it has a cysteine nucleophile but with a chymotrypsin-like serine protease folding. This unique protein structure together with its essential role in viral replication made the 3Cpro an excellent target for antiviral intervention. In recent years, considerable efforts have been made in the development of antiviral compounds targeting this enzyme. To further facilitate the design of potent 3C protease inhibitors for therapeutic use, this review summarizes the biochemical and structural characterization conducted on HRV 3C protease along with the recent progress on the development of 3C protease inhibitors.
Similar articles
-
Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication.J Med Chem. 1998 Jul 2;41(14):2579-87. doi: 10.1021/jm980114+. J Med Chem. 1998. PMID: 9651162
-
Protease inhibitors as potential antiviral agents for the treatment of picornaviral infections.Prog Drug Res. 2001;Spec No:229-53. doi: 10.1007/978-3-0348-7784-8_6. Prog Drug Res. 2001. PMID: 11548209 Review.
-
Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.Bioorg Med Chem Lett. 2018 Mar 1;28(5):906-909. doi: 10.1016/j.bmcl.2018.01.064. Epub 2018 Feb 1. Bioorg Med Chem Lett. 2018. PMID: 29433930
-
Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease.Bioorg Med Chem Lett. 2016 Jul 15;26(14):3248-3252. doi: 10.1016/j.bmcl.2016.05.066. Epub 2016 May 24. Bioorg Med Chem Lett. 2016. PMID: 27265257
-
Protease inhibitors as potential antiviral agents for the treatment of picornaviral infections.Prog Drug Res. 1999;52:197-219. doi: 10.1007/978-3-0348-8730-4_5. Prog Drug Res. 1999. PMID: 10396129 Review.
Cited by
-
Phytochemicals: Promising Inhibitors of Human Rhinovirus Type 14 3C Protease as a Strategy to Fight the Common Cold.Curr Top Med Chem. 2024;24(15):1343-1358. doi: 10.2174/0115680266308561240427065854. Curr Top Med Chem. 2024. PMID: 38698747
-
On the origins of SARS-CoV-2 main protease inhibitors.RSC Med Chem. 2023 Oct 13;15(1):81-118. doi: 10.1039/d3md00493g. eCollection 2024 Jan 25. RSC Med Chem. 2023. PMID: 38283212 Free PMC article. Review.
-
Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.Antimicrob Agents Chemother. 2009 Feb;53(2):748-55. doi: 10.1128/AAC.00841-08. Epub 2008 Nov 17. Antimicrob Agents Chemother. 2009. PMID: 19015331 Free PMC article.
-
Lab-on-a-chip for the easy and visual detection of SARS-CoV-2 in saliva based on sensory polymers.Sens Actuators B Chem. 2023 Mar 15;379:133165. doi: 10.1016/j.snb.2022.133165. Epub 2022 Dec 15. Sens Actuators B Chem. 2023. PMID: 36536612 Free PMC article.
-
Inhibitors of polyhydroxyalkanoate (PHA) synthases: synthesis, molecular docking, and implications.Chembiochem. 2015 Jan 2;16(1):156-166. doi: 10.1002/cbic.201402380. Epub 2014 Nov 13. Chembiochem. 2015. PMID: 25394180 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials